0OP Stock Overview
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OptiNose, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$1.82 |
| 52 Week Low | US$0.81 |
| Beta | -0.24 |
| 1 Month Change | -45.01% |
| 3 Month Change | -19.28% |
| 1 Year Change | -47.08% |
| 3 Year Change | -69.20% |
| 5 Year Change | -89.41% |
| Change since IPO | -94.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0OP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -45.0% | -3.3% | -1.5% |
| 1Y | -47.1% | -30.8% | 0.9% |
Return vs Industry: 0OP underperformed the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: 0OP underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 0OP volatility | |
|---|---|
| 0OP Average Weekly Movement | 19.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0OP's share price has been volatile over the past 3 months.
Volatility Over Time: 0OP's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 132 | Ramy Mahmoud | www.optinose.com |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
OptiNose, Inc. Fundamentals Summary
| 0OP fundamental statistics | |
|---|---|
| Market cap | €107.95m |
| Earnings (TTM) | -€33.34m |
| Revenue (TTM) | €66.69m |
1.5x
P/S Ratio-2.9x
P/E RatioIs 0OP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0OP income statement (TTM) | |
|---|---|
| Revenue | US$70.99m |
| Cost of Revenue | US$8.63m |
| Gross Profit | US$62.35m |
| Other Expenses | US$97.84m |
| Earnings | -US$35.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 87.84% |
| Net Profit Margin | -49.99% |
| Debt/Equity Ratio | -150.4% |
How did 0OP perform over the long term?
See historical performance and comparison